Results 211 to 220 of about 103,779 (258)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

The Latent Dimensionality of Physical and Technical Performance Across Three Youth Soccer Tiers. [PDF]

open access: yesJ Funct Morphol Kinesiol
Preljević A   +13 more
europepmc   +1 more source

Prenatal exposure to maternal steroid hormones and child neurodevelopment: evidence for sex-specific effects in a longitudinal birth cohort

open access: yes
Renard-Dausset E   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy